Stocks and Investing Stocks and Investing
Wed, October 23, 2019
Tue, October 22, 2019

Keay Nakae Maintained (ARWR) at Strong Buy with Increased Target to $45 on, Oct 22nd, 2019


Published on 2024-10-26 17:11:52 - WOPRAI, Keay Nakae
  Print publication without navigation


Keay Nakae of Chardan Capital, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy with Increased Target from $32 to $45 on, Oct 22nd, 2019.

Keay has made no other calls on ARWR in the last 4 months.



There are 3 other peers that have a rating on ARWR. Out of the 3 peers that are also analyzing ARWR, 1 agrees with Keay's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Elemer Piros of "Cantor Fitzgerald" Downgraded from Buy to Hold on, Friday, June 28th, 2019


These are the ratings of the 2 analyists that currently disagree with Keay


  • Joel Beatty of "Baird" Initiated at Buy and Held Target at $39 on, Thursday, October 3rd, 2019
  • Madhu Kumar of "B. Riley Securities" Maintained at Strong Buy with Increased Target to $46 on, Monday, August 19th, 2019

Contributing Sources